Kwasi Gambrah, MD
Family Medicine · Charleston, WVNPI 1447811872
Payments from drug & device makers
Across 263 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$848
- AbbVie$785
- Amgen$528
- AstraZeneca$348
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$311
- Novartis$286
- plus $1K from 19 others
What the payments were for
- Food & beverage$4,598100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 50 | $848 |
| AbbVie | 46 | $785 |
| Amgen(2 entities) | 31 | $528 |
| AstraZeneca | 17 | $348 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $311 |
| Novartis | 15 | $286 |
| GSK | 12 | $191 |
| Pfizer | 9 | $187 |
| Lilly USA, LLC | 11 | $171 |
| Astellas Pharma US Inc | 8 | $157 |
| Sumitomo Pharma America, Inc. | 8 | $147 |
| Abbott | 6 | $121 |
| Dexcom, Inc. | 6 | $113 |
| Bayer | 4 | $67 |
| Phathom Pharmaceuticals, Inc. | 5 | $55 |
| Shield Therapeutics Inc | 3 | $49 |
| Mylan Specialty L.p. | 2 | $38 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Exact Sciences | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Corcept Therapeutics | 1 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$4,598 in reported general payments places this provider in the 85th percentile of 843 family medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 130 | $141,019 |
| OzempicSemaglutide | 82 | $119,052 |
| JardianceEmpagliflozin | 50 | $70,960 |
| TrulicityDulaglutide | 49 | $61,642 |
| JanuviaSitagliptin Phosphate | 38 | $51,749 |
| FarxigaDapagliflozin Propanediol | 35 | $50,434 |
| RybelsusSemaglutide | 18 | $33,686 |
| MounjaroTirzepatide | 13 | $28,729 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $25,205 |
| Nurtec OdtRimegepant Sulfate | 14 | $25,063 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $24,817 |
| EntrestoSacubitril/Valsartan | 15 | $23,303 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $23,273 |
| LinzessLinaclotide | 13 | $16,996 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $11,758 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $187 | $166,082144 claims |
| Novo NordiskOzempic, Rybelsus | $848 | $152,738100 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $171 | $90,37162 claims |
| Boehringer IngelheimJardiance | $14 | $70,96050 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $348 | $64,96364 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $191 | $38,08872 claims |
| NovartisEntresto | $286 | $23,30315 claims |
| AbbVieLinzess, Synthroid | $785 | $19,40553 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 843 family medicine providers in West Virginia.
Other family medicine in Charleston
- Melissa GamponiaCharleston$18K
- Donald MooreCharleston$17K
- John LewisCharleston$11K
- Mark RichardsCharleston$10K
- Wilbur SineMorgantown$179K
- Dorian WilliamsMorgantown$169K
- Julie DetempleSouth Charleston$129K
- Clemente DiazRichwood$127K
- John CornellHuntington$94K
- Mark CucuzzellaHarpers Ferry$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.